Premium
Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
Author(s) -
Diebold Martin,
Galli Edoardo,
Kopf Andreas,
Sanderson Nicholas,
Callegari Ilaria,
Ingelfinger Florian,
Núñez Nicolás Gonzalo,
Benkert Pascal,
Kappos Ludwig,
Kuhle Jens,
Becher Burkhard,
Claassen Manfred,
Derfuss Tobias
Publication year - 2022
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.26328
Subject(s) - dimethyl fumarate , multiple sclerosis , immune system , immunology , mass cytometry , population , biomarker , observational study , flow cytometry , medicine , cell , expanded disability status scale , oncology , biology , biochemistry , gene , environmental health , phenotype
Treatment with dimethyl fumarate (DMF) leads to lymphopenia and infectious complications in a subset of patients with multiple sclerosis (MS). Here, we aimed to reveal immune markers of DMF‐associated lymphopenia. This prospective observational study longitudinally assessed 31 individuals with MS by single‐cell mass cytometry before and after 12 and 48 weeks of DMF therapy. Employing a neural network‐based representation learning approach, we identified a CCR4‐expressing T helper cell population negatively associated with relevant lymphopenia. CCR4‐expressing T helper cells represent a candidate prognostic biomarker for the development of relevant lymphopenia in patients undergoing DMF treatment. ANN NEUROL 2022;91:676–681